Company intelligence / Profile preview
Diapin Therapeutics
Northville, Michigan, United Statesdiapin.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Diapin Therapeutics is developing DT678, a novel prodrug that directly forms the active metabolite of clopidogrel without hepatic activation, potentially ensuring consistent efficacy across all patient populations including those with CYP2C19 mutations. The company has received FDA feedback for potential expedited development of DT678 as a promising antiplatelet therapy. Their second program, DT109, is a tripeptide targeting multiple indications including MASH, Primary Biliary Cholangitis, and Type 2 Diabetes.[5]
- Therapeutic areas
- Metabolic DisordersEndocrinologyGastroenterologyCardiovascularNeurology
- Modalities
- Small molecule drugsRecombinant polypeptidesPeptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Diapin Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diapin Therapeutics.